BETA
This is a BETA experience. You may opt-out by clicking here

More From Forbes

Edit Story

ESC Hot Lines: First Real Data On Promising Novartis Heart Failure Drug

Following
This article is more than 9 years old.

The first real details about the much-anticipated novel new heart failure drug from Novartis will kick off this year's Hot Line sessions at the annual meeting of the European Society of Cardiology in Barcelona, Spain. The meeting runs from August 30 until September 3.

As I have previously reported, the PARADIGM-HF trial was stopped because of a highly statistically significant reduction in cardiovascular mortality in patients taking LCZ696 (a novel, first-in-class Angiotensin Receptor Neprilysin Inhibitor) instead of the current gold standard of treatment, an ACE inhibitor. Until we see the data it is impossible to reach any conclusions, but it should be noted that there would be enormous clinical and business implications if a new drug  becomes a standard of therapy for millions of people with heart failure.

Another presentation that will likely attract a lot of interest is the SIGNIFY trial with the drug ivabradine, which is marketed in Europe by Servier and is under development in the US by Amgen. As I have previously reported, the European Medicines Agency said that it has started a review of the drug based on troubling findings from the trial.

Also sure to attract interest will be 2 presentations on the new PCSK9 inhibitor aliorcumab under development by Sanofi and Regeneron. Chris Cannon will present results of the Odyssey Combo II study in high risk patients with inadequately controlled hypercholesterolemia on maximally tolerated daily statin. Michel Farnier will present results of the ODYSSEY FH I and FH II studies in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy.

Here is the complete list of Hot Line trials:

Hot Line: Cardiovascular disease: novel therapies

  • 31 Aug 08:30 - 10:20
  • Chairpersons: Mariell JESSUP (Philadelphia, US), Hector BUENO (Madrid, ES)

08:30 Results of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF) Milton PACKER (Dallas, US)

  • Discussant: Michel KOMAJDA (Paris, FR)

08:48 A randomized controlled trial of vagal stimulation for the treatment of systolic heart failure: NEural Cardiac TherApy foR Heart Failure (NECTAR-HF) Faiez ZANNAD (Vandoeuvre Les Nancy, FR)

  • Discussant: John CAMM (London, GB)

09:06 Effect of ferric carboxymaltose on functional capacity in patients with heart failure and iron deficiency (CONFIRM-HF) Piotr PONIKOWSKI (Wroclaw, PL)

  • Discussant:  Harry CRIJNS (Maastricht, NL)

09:24 Cardiac resynchronization therapy with a novel quadripolar lead decreases complications at six months: preliminary results of the MORE-CRT trial Giuseppe BORIANI (Bologna, IT)

  • Discussant: John CLELAND (London, GB)

09:42 Colchicine for Post- operative Pericardial Effusion: The post-operative pericardial effusion (POPE-2) Study. A multicenter, double-blind, randomized trial Philippe MEURIN (Villeneuve-St.-Denis, FR)

  • Discussant: Jae K OH (Rochester, US)

10:00 COlchicine for Prevention of the Post-pericardiotomy Syndrome and Post-operative Atrial Fibrillation (COPPS-2 trial) Massimo IMAZIO (Torino, IT)

  • Discussant: Stavros V KONSTANTINIDES (Mainz, DE)

Hot Line: Coronary artery disease and lipids

  • 31 Aug 16:30 - 18:00 Miscellaneous Hot Line Barcelona - Central Village
  • Chairpersons: John Gordon HAROLD (Los Angeles, US), Fausto Jose PINTO (Lisbon, PT)

16:30 The Stabilization Of pLaques usIng Darapladib-Thrombolysis in Myocardial Infarction 52 (SOLID-TIMI 52) trial: Primary Results Michelle O'DONOGHUE (Boston, US)

  • Discussant: Robert M CALIFF (Durham, US)

16:48 Ivabradine in patients with stable coronary artery disease without clinical heart failure: The results of SIGNIFY Kim FOX (London, GB)

  • Discussant: Jean-Pierre BASSAND (Thise, FR)

17:06 Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated daily statin: results from the ODYSSEY COMBO II study Christopher Paul CANNON (Boston, US)

  • Discussant: Thomas Felix LUSCHER (Zurich, CH)

17:24 Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolaemia not adequately controlled with current lipid-lowering therapy: results of ODYSSEY FH I and FH II studies Michel FARNIER (Dijon, FR)

  • Discussant: Thomas Felix LUSCHER (Zurich, CH)

17:42 The differences of the effects on lipid-lowering actions and glucose metabolisms between rosuvastatin and atorvastatin in Japanese diabetic patients with hyperlipidemia Hisao OGAWA (Kumamoto, JP)

  • Discussant: John CHAPMAN (Paris, FR)

Hot Line: Heart failure: devices and interventions

  • 1 Sep 11:00 - 12:50 Miscellaneous Hot Line Barcelona - Central Village
  • Chairpersons: Hisao OGAWA (Kumamoto, JP), Panagiotis VARDAS (Heraklion, GR)

11:00 Randomized comparison of a novel, ultrathin strut biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent for percutaneous coronary revascularization Thomas PILGRIM (Bern, CH)

  • Discussant review Patrick SERRUYS (Rotterdam, NL)

11:18 Autonomic regulation therapy for the improvement of left ventricular function and heart failure symptoms: The ANTHEM-HF Study Inder ANAND (Minneapolis, US)

  • Discussant review Gerhard HINDRICKS (Leipzig, DE)

11:36 Biventricular pacing for atrIo-ventricular BlOck to Prevent cArdiaC dEsynchronization Jean-Jacques BLANC (Brest, FR)

  • Discussant review Patrick SCHAUERTE (Berlin, DE)

11:54 Comparison of right ventricular septal pacing and right ventricular pacing in patinets receiving a CRT-D Christophe LECLERCQ (Rennes, FR)

  • Discussant review Jagmeet SINGH (Boston, US)

12:12 Optimal method and outcomes of catheter ablation of persistent atrial fibrillation: Results of the Prospective, Randomized STAR AF 2 Trial Atul VERMA (Newmarket, CA)

  • Discussant review Paulus KIRCHHOF (Birmingham, GB)

12:30 EuroEco (European Health Economic Trial on Home Monitoring in ICD Patients): a provider perspective on follow-up costs and net financial impact of remote monitoring in six European countries Hein HEIDBUCHEL (Leuven, BE)

  • Discussant review Carina BLOMSTROM-LUNDQVIST (Uppsala, SE)

Hot Line: Myocardial Infarction

  • 1 Sep 16:30 - 18:00 Miscellaneous Hot Line Barcelona - Central Village
  • Chairpersons: Lars WALLENTIN (Uppsala, SE), Karl-Heinz KUCK (Hamburg, DE)

16:30 Complete versus Lesion only PRimary -PCI Trial (CvLPRIT): Treat the infarct related artery only or all lesions Anthony H GERSHLICK (Leicester, GB)

  • Discussant review Shamir R MEHTA (Hamilton, CA)

16:48 In-ambulance versus in-cath lab administration of ticagrelor in STEMI patients transferred for primary PCI: the randomized, double-blind ATLANTIC study Gilles MONTALESCOT (Paris, FR)

  • Discussant review Paul Wayne ARMSTRONG (Edmonton, CA)

17:06 The British Heart Foundation Fractional Flow Reserve versus Angiography in Guiding Management to Optimise Outcomes in Non-ST-Segment Elevation Myocardial Infarction Colin BERRY (Glasgow, GB)

  • Discussant review Bernard DE BRUYNE (Aalst, BE)

17:24 Nitric oxide for inhalation to reduce reperfusion injury in acute st-elevation myocardial infarction

  • Discussant review Michael MARBER (London, GB)

17:42 Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: Results of the MITOCARE study Dan ATAR (Oslo, NO)

  • Discussant review Hans Erik BOTKER (Aarhus N, DK)

Hot Line: Coronary artery disease and atrial fibrillation

  • 2 Sep 11:00 - 12:30 Miscellaneous Hot Line Barcelona - Central Village
  • Chairpersons: Keith FOX (Edinburgh, GB)

11:00 Perioperative statin treatment in cardiac surgery for the prevention of atrial fibrillation and perioperative myocardial damage: the Statin Therapy In Cardiac Surgery (STICS) Trial Barbara CASADEI (Oxford, GB)

  • Discussant review Paulus KIRCHHOF (Birmingham, GB)

11:18 The X-VERT Trial: A comparison of oral rivaroxaban once daily with dose-adjusted Vitamin K Antagonists in patients with nonvalvular atrial fibrillation undergoing elective cardioversion Riccardo CAPPATO (San Donato Milanese, IT)

  • Discussant review Christoph BODE (Freiburg, DE)

11:36 Recurrence of arrhythmia following short-term oral AMIOdarone after CATheter ablation for atrial fibrillation: A double-blind, randomized, placebo-controlled study Stine DARKNER (Copenhagen, DK)

11:54 Effect of high-intensity statin therapy on atherosclerosis in patients with ST-elevation myocardial infarction: Results of the prospective, longitudinal intravascular ultrasound follow-up study Lorenz RABER (Bern, CH)

  • Discussant review Steven E NISSEN (Cleveland, US)

12:12 IMPI Steroid Study: A Trial of Adjunctive Prednisolone in Tuberculous Pericarditis Bongani Mawethu MAYOSI (Cape Town, ZA)